论文部分内容阅读
目的探讨诺和锐30治疗老年糖尿病的临床观察。方法 2009年1月至2010年2月门诊或住院的符合入选标准的老年糖尿病患者248例,诺和锐30组128例采用诺和锐30特充笔于早、晚餐前10 m in即刻皮下注射;诺和灵30R组120例采用诺和灵30R用诺和笔于早、晚餐前30 m in皮下注射,观察两组血糖情况及低血糖事件发生情况。结果两组空腹、午餐前、晚餐前、睡前血糖检测P>0.05差异无统计学意义。两组早餐后、午餐后、晚餐后血糖检测P<0.05差异有统计学意义。两组胰岛素用量比较P<0.05差异有统计学意义。两组轻微发作低血糖事件发生率比较P>0.05差异无统计学意义;两组严重发作低血糖事件比较P<0.05差异有统计学意义。结论诺和锐30具有控制血糖平稳,尤其对餐后血糖的控制更为有效.减少了下餐前低血糖的危险性,减少胰岛素用量,更有利于糖尿病血糖控制,更有利于老年患者应用。
Objective To investigate the clinical observation of Novo Rui 30 in the treatment of senile diabetes. Methods A total of 248 elderly patients with diabetes mellitus who met the inclusion criteria from January 2009 to February 2010 were enrolled in this study. Nuo-Rui-Rui Group 30 (n = 128) ; 120mg noradren 30R group were treated with Novolin 30R with Nouhe pen at 30 mins before breakfast and evening subcutaneous injection. The incidence of hypoglycemia and blood glucose were observed. Results There was no significant difference in fasting, pre-lunch, pre-dinner and before-bedtime blood glucose test for P> 0.05. After two groups of breakfast, after lunch, postprandial blood glucose test P <0.05 difference was statistically significant. The two groups of insulin dosage comparison P <0.05 difference was statistically significant. There was no significant difference in the incidence of mild episodes of hypoglycaemia between the two groups (P> 0.05). There was significant difference between the two groups in the incidence of severe hypoglycaemia (P <0.05). Conclusions Nuo-Rui-Rui 30 can control the blood sugar stable, especially for the control of postprandial blood glucose more effectively reduce the risk of hypoglycemia before meals, reduce the amount of insulin, more conducive to diabetes, blood sugar control, more conducive to the elderly patients.